Tourmaline Bio to Present at Upcoming Investor Conferences
Rhea-AI Summary
Tourmaline Bio (NASDAQ: TRML) has announced its participation in two upcoming investor conferences. Dr. Sandeep Kulkarni, Co-Founder and CEO, will participate in the Truist Securities BioPharma Symposium in New York on November 7, 2024, speaking on a panel about cardiac and skeletal muscle illnesses at 2:35 pm ET. He will also join a fireside chat at the Guggenheim Securities Healthcare Innovation Conference in Boston on November 12, 2024, at 1:30 pm ET.
Live webcasts and replays will be accessible through the company's investor relations website at ir.tourmalinebio.com under 'Events and Presentations.'
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TRML declined 3.63%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conferences:
Truist Securities BioPharma Symposium, New York
Panel: Close to Heart: Innovative Approaches to Targeting Cardiac & Skeletal Muscle Illnesses
Thursday, November 7, 2024 at 2:35 pm ET
Guggenheim Securities Healthcare Innovation Conference, Boston
Fireside Chat
Tuesday, November 12, 2024 at 1:30 pm ET
Live webcasts and replays, when available, will be available under "Events and Presentations" in the News & Investors section of the Tourmaline Bio website at ir.tourmalinebio.com.
For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X.
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).
Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com
Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
FAQ
When is Tourmaline Bio (TRML) presenting at the Truist Securities BioPharma Symposium?
What conferences is Tourmaline Bio (TRML) attending in November 2024?
Where can investors watch Tourmaline Bio's (TRML) conference presentations?
